Marker Therapeutics, Inc.MRKRNASDAQ
Loading
MRKR Revenue Growth (YoY Quarterly)•-51.00%
Stock Alarm Pro
Growth Metrics
Latest: Q4 2025vs Q3 2025
Revenue GrowthGross Profit GrowthEBITDA GrowthOperating Income GrowthNet Income GrowthEPS GrowthEPS Diluted GrowthWeighted Average Shares GrowthWeighted Average Shares Diluted GrowthDividends per Share Growth
-51.00%
-15.0pp
+0.00%
+0.0pp
+0.00%
+0.0pp
+0.00%
+0.0pp
+0.00%
+0.0pp
+0.00%
+0.0pp
+0.00%
+0.0pp
+68.22%
-19.6pp
+68.22%
-19.6pp
+0.00%
+0.0pp
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 |
|---|---|---|---|---|---|
| Revenue Growth | +113.13% | -71.94% | -26.35% | -35.98% | -51.00% |
| Gross Profit Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EBITDA Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Net Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Diluted Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Weighted Average Shares Growth | +2.26% | +24.76% | +56.50% | +87.80% | +68.22% |
| Weighted Average Shares Diluted Growth | +2.26% | +24.76% | +56.50% | +87.80% | +68.22% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | +0.00% | +0.00% | +0.00% | -328.47% | +0.00% |
| Free Cash Flow Growth | +0.00% | +0.00% | +0.00% | -328.47% | +0.00% |
| Receivables Growth | +128.32% | +32.80% | -32.76% | +123.69% | -41.66% |
| Inventory Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Asset Growth | +28.58% | +20.59% | +26.49% | +99.21% | +86596268.50% |
| Book Value per Share Growth | +29.15% | -1.46% | -30.91% | +31.44% | +53802116.19% |
| Debt Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| R&D Expense Growth | +94.33% | +21.76% | +78.86% | -32.42% | +231984121.22% |
| SG&A Expenses Growth | -25.42% | +12.41% | -17.23% | +19.79% | +407479837.80% |
1 / 4